



In Support of Life
Press Release
New Delhi
28 June 2007

For Immediate Release

Panacea Biotec forays into Cancer treatment

Panacea Biotec has plans to forays into oncology segment to provide treatment for breast cancer, brain tumor, ovarian cancer, pancreatic cancer, prostate cancer and colorectal cancer. The company plans to launch seven anti-cancer products in the next 8 weeks. These drugs will be manufactured by a Mumbai based company to be sold under the brand name of Panacea Biotec.

'**Oncotrust**' would be the new Strategic Business Unit (SBU) of Panacea Biotec with the total strength of 50 sales specialists on oncology who would be responsible for marketing the drugs. The aim is to register sales volumes of Rs.15-20 crores in oncology chemotherapy segment in the next three years. The company feels that it would be able to launch novel drug delivery based anti-cancer drug in next 2-3 year period.

"We plan to develop novel and innovative drug delivery systems (NDDS) of the existing anti-cancer molecule. The new research based drug development will take 2-3 years as we need to develop an effective distribution chain & occupy a significant market share in oncology drugs." Says, Mr. Rajesh Jain, Joint Managing Director, Panacea Biotec.

The company also plans to launch its Injectable Polio Vaccine (IPV) in next three months in the private market and would gradually increase the market share after post polio eradication programme of Govt. of India.

Recently, **Panacea Biotec** announced its excellent results for FY'07. It has registered a 53% increase in its gross turnover at Rs. 839.8 crore and reported a sharp rise of 140.9% in its net profit at Rs. 146.8 crore for the year ended March 31, 2007, compared to previous year.

About Oncology

The overall size of the domestic oncology market is about Rs.800 crore and is growing at 22%. More than 50 percent of the world's cancer burden, in terms of both numbers of cases and deaths, occurs in developing countries. Based on the cancer registry data it is estimated that there will be about 800,000 new cancer cases in India every year. The leading cancer amongst females is breast cancer and uterus, while amongst men are prostate cancer, lung cancer and colorectal cancer.



About Panacea Biotec:

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology Company (ABLE Survey 2006) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. The Company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The Company has four research and development centers. The Company has over 2300 employees including over 200 scientists. The Company also has 10 international product patents.

For further details please contact:

Pradeep Kumar Jain

GM - Corporate Communications

Mobile: 9313482886, Ph: 011-41678000 Fax: 011-26940199

Email: pradeepjain@panaceabiotec.com